Biomarkers in GIST: Partly Ready for Prime-Time Use

Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research , two articles discuss biomarkers potentially helpful in predicting response or other long-term b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2009-09, Vol.15 (18), p.5603-5605
1. Verfasser:	Blanke, Charles D
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - metabolism Disease Progression Gastrointestinal Stromal Tumors - diagnosis Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - enzymology Gastrointestinal Stromal Tumors - metabolism Humans Indoles - pharmacology Indoles - therapeutic use Predictive Value of Tests Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-kit - antagonists & inhibitors Proto-Oncogene Proteins c-kit - metabolism Pyrroles - pharmacology Pyrroles - therapeutic use Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research , two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use. (Clin Cancer Res 2009;15(18):5603–5)
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-09-1563